House Research

- Bill Summary :

File Number: H.F. 3196 Date: March 20, 2018

Version: First engrossment

Authors: Fenton

Subject: Step Therapy Protocol Override

Analyst: Larie Ann Pampuch (larie.pampuch@house.mn)

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: www.house.mn/hrd/.

Overview

This bill creates a process by which an enrollee and prescribing health care provider can override a health plan company's step therapy protocol (the protocol that requires an enrollee to use a specific prescription medication before receiving a different prescription medication).

Section

- 1 [62Q.184] Step therapy override.
 - **Subd. 1. Definitions.** Provides definitions.
 - **Subd. 2. Establishment of a step therapy protocol.** Requires health plan companies to establish a step therapy protocol based on clinical practice guidelines and provide an enrollee with the applicable clinical review criteria upon request.
 - Subd. 3. Step therapy override process; transparency. (a) Requires that if a health plan company restricts the use of a drug, they must provide a clear and convenient process for health care providers and enrollees to request an override. The process must be available on the health plan company's website and a health plan company that has an existing medical exceptions process can continue to use that process. An override must be granted if the drug or enrollee meets certain conditions.
 - (b) Provides that a health plan company cover a covered prescription after an override is granted.
 - (c) Clarifies that an enrollee or provider can appeal the denial of an override using the complaint procedure in sections 62Q.68 to 62Q.73.

H.F. 3196 March 20, 2018 Version: First engrossment Page 2

Section

- (d) Requires a health plan company to state why a step therapy override was not granted and provide information regarding a request for an external review of the denial under section 62Q.73. Provides that a denial that is upheld on appeal is final and is then eligible for a request for external review.
- (e) Requires a health plan company to respond for a request for an override or an appeal within 5 days, or within 72 hours if there are exigent circumstances. Provides that if a health plan company does not respond within these time limits the request is granted.
- (f) Requires step therapy override requests be accessible to health care providers and allow them to submit the request to group purchasers electronically.
- (g) Clarifies that nothing in this section prohibits a health plan company from requesting relevant medical records, requiring an enrollee to try a generic or biosimilar equivalent before covering a branded drug, or using drug samples to meet the step therapy override requirements.
- (h) Clarifies that this section cannot be construed to allow a drug sample to serve the primary purpose of a step therapy override.

Effective date. This section is effective January 1, 2019, and applies to health plans after that date.